Background: The incidence of chronic kidney disease (CKD) is relatively high in Guyana. eGFR (estimated
INTRODUCTION
Chronic kidney disease (CKD) is a major public health problem with increasing prevalence Worldwide due to the increased incidence of diabetes and hypertension (1) . Left untreated, CKD can progress to end-stage renal disease (ESRD) requiring hemodialysis. Hemodialysis is widely available for the treatment of ESRD in the developed World but this is often not the case in developing countries where a diagnosis of ESRD often results in death (2) .
According to a Pan American Health Organization strategy report from 2014 (3), chronic diseases now represent the most significant healthcare challenge in Guyana, surpassing communicable diseases. Each year 8000 new cases of diabetes are diagnosed in this country. It is well recognized that many of these patients will go on to develop kidney disease as an associated complication of the diabetic disease process. CKD leading to ESRD is a healthcare challenge in Guyana where dialysis is scarcely available and, where available, is often prohibitively expensive for those requiring it. The cost of one dialysis session in Guyana is currently $52.76 US according to the Doobay Medical Centre, which operates 24 of the country's 37 available dialysis machines.
Earlier detection of CKD has been shown to optimize care through dietary and lifestyle modifications, leading to better patient outcomes (4, 5 for kidney disease assigns patients to one of six stages of disease on the basis of a calculated eGFR. Reporting of eGFR and classification of patients based on their calculated eGFR requires standardization of creatinine methods to minimize systemic differences between laboratory methods (9). International initiatives aimed at standardizing creatinine measurements have been undertaken in the Developed World (9) but have not been widely implemented throughout the Developing World.
The current study was undertaken to assess the accuracy of creatinine measurements in Guyana and to provide an estimation of the potential impact that creatinine standardization could have on the eGFR staging of kidney disease in the Guyanese population.
METHODS

Participating Laboratories
A total of sixteen laboratories (public and private) agreed on a voluntary basis to participate in the study. A confidentiality agreement was put in place with each laboratory confirming that only aggregated (non-identifying) performance data from the study would be made public. This was necessary to enhance the rate of participation.
Reference Samples
Each laboratory received a common set (n=3) of human serum samples. The creatinine concentrations in these samples were blinded to the end-users and covered the clinical range of interest for the early diagnosis of kidney disease (stage 3). The reference values as assigned by an internationally credentialed reference method for the measurement of this analyte (isotopedilution mass spectrometry) were as follows:
Reference Sample Analysis
Participating laboratories were asked to measure creatinine in each of the samples three times on each of three days for a total of twenty-seven measurements (nine measurements for each reference sample). The mean of the nine results for each sample was compared to the assigned reference values using linear regression. From these data the within-sample between-day imprecision, the bias and total error of measurement (TE = %bias + 1.65 CV) were calculated for each lab.
Patient Data
Each participating laboratory was asked to provide the age, gender and test results for the last one hundred reported creatinine results from their lab. These data were used for the calculation of eGFR (CKD-EPI) before and after applying a correction for calibration bias. These calculations provided an estimation of the potential benefit that could be realized from the standardization of the lab's creatinine method.
Results
The various combinations of creatinine methods, reagents and calibrators in-use by the participating laboratories are summarized in Table 1 . The majority of the labs were using open heterogeneous methods for the measurement of creatinine. This decision reflected a desire to use less expensive reagents. It is noteworthy that the best overall performing laboratory in the study was using a closed homogeneous testing system.
Method Imprecision
Laboratories measured each reference creatinine sample three times throughout the day on each of three consecutive days.
Measurement imprecision was calculated at each creatinine concentration. The average, minimum and maximum CVs at each reference creatinine concentration are presented in Table 2 . The average across sample total measurement error exhibited by each laboratory is presented in Figure 1 together with the lab's average across sample precision.
Method Bias
Method bias for each laboratory was calculated by comparing the target value for each reference creatinine sample as assigned by the reference method to the measured creatinine value (mean of nine values) reported by each participating laboratory. The mean % bias (all labs) is presented in Table 3 with the minimum and maximum reported values.
Retrospective eGFR Classification of Patients in Guyana
Laboratories were asked to submit their most recently reported 100 creatinine test results together with the age and gender of the patient tested. These data were used in calculating the eGFR by the CKD-EPI equation (8) before and after correcting the lab's creatinine method for calibration bias. The impact of calibration bias was determined by comparing the percentage of patients classified within each of the five eGFR categories before and after bias correction of the reported creatinine test result that was used in the calculation. From these data, the percentage of missclassified patients at each eGFR stage was calculated.
Many of the labs were found to be operating methods with very poor precision.
In order to provide an estimate of the potential improvement that could be realized from the standardization of creatinine testing in Guyana, a sub-set of the better performing labs (average across sample CV of 7% or less) was selected for this analysis. Nine of the 16 labs were qualified accordingly and only one laboratory was operating a creatinine method with a desirable CV of 1 and 2 ). This would provide opportunities for earlier interventions to prevent the risk of disease and for slowing the rate of disease progression.
DISCUSSION
There are several different instrument types in use in Guyana. The majority are using Jaffe heterogeneous reagent/calibrator systems for the measurement of creatinine. There was only one closed homogeneous system operating in the country. This laboratory had the best overall performance of all the labs studied. Heterogeneous testing systems are less costly but their use introduces many confounding factors that have a negative impact on the overall quality and accuracy of the creatinine test results produced. This was certainly a contributing factor to the high error rates observed in this study.
Measurement imprecision was a significant problem for the majority of the labs. Only two of the labs were operating systems that were precise enough to warrant standardization. Onsite investigations of lab practice identified a number of factors that would have a negative impact on precision. Paramount among these was the poor environmental control that was being exercised for maintaining the temperature and humidity in the lab at acceptable levels as required for the optimal performance of the method and the analyzer. Although the majority of labs were operating internal quality control (IQC) systems, these systems were not being used properly for monitoring the performance of their creatinine method. Method performance was being monitored on the basis of the manufacturer's suggested performance targets and ranges as opposed to those established on the basis of "in house" method performance. This would essentially preclude the identification of significant changes in performance.
The majority of the labs in this study were operating creatinine methods with a positive calibration bias, a reality that would significantly increase the number of false positives with population based eGFR screening. There was no evidence that the calibrator set points were traceable to internationally recognized standards for the measurement of creatinine and most of the labs were using a single point calibration curve that was being forced through zero.
The patient test result data from each lab were used to retrospectively calculate the eGFR that the laboratory would have reported on the basis of the performance of their current creatinine method. The eGFR was then re-calculated for these patients after the lab's creatinine method had Strategies aimed at improving the precision of laboratory creatinine methods followed by standardization efforts to improve method bias, will be needed for the laboratories in Guyana to report accurate eGFR results. Achieving this goal will be essential for clinicians in Guyana to accurately identify CKD in their patients and to provide their "at risk" patients with guidance on diet and lifestyle modifications aimed at preventing or slowing progression their disease.
The economic impact of inaccurate lab tests on health care delivery systems is seldom a topic of discussion in peer reviewed publications. In light of the limited resources and the scarcity of funds for healthcare delivery in Guyana, the question should be asked as to whether or not it would be cost effective to standardize the measurement of creatinine in the country.
The standardization of creatinine testing could be achieved through the use of accuracy based internal quality control samples (three levels) that would be analyzed once a week for improving and monitoring the accuracy of the lab's creatinine testing method. Figure: The average imprecision for each lab over measurement of three reference creatinine samples was calculated and is shown alongside the average total error for creatinine measurements over three reference creatinine samples.
